Cycloserine - Tikvah Therapeutics

Drug Profile

Cycloserine - Tikvah Therapeutics

Alternative Names: D-cycloserine - Tikvah; TIK-101

Latest Information Update: 04 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Therapade Technologies LLC
  • Developer Tikvah Therapeutics
  • Class Antituberculars; Isoxazoles; Small molecules
  • Mechanism of Action NMDA receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Obsessive-compulsive disorders; Panic disorder; Phobic disorders; Post-traumatic stress disorders; Social phobia

Most Recent Events

  • 02 Aug 2007 Phase-II clinical trials in Obsessive-compulsive disorders in USA (unspecified route)
  • 02 Aug 2007 Phase-II trials in Phobic disorders in USA (unspecified route)
  • 02 Aug 2007 Phase-II trials in Post-traumatic stress disorder in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top